Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Operations: 2019-2024

Historic Cash from Operations for Day One Biopharmaceuticals (DAWN) over the last 6 years, with Dec 2024 value amounting to -$78.1 million.

  • Day One Biopharmaceuticals' Cash from Operations fell 111.44% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.6 million, marking a year-over-year decrease of 33.68%. This contributed to the annual value of -$78.1 million for FY2024, which is 46.81% up from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Cash from Operations stood at -$78.1 million for FY2024, which was up 46.81% from -$146.9 million recorded in FY2023.
  • Day One Biopharmaceuticals' Cash from Operations' 5-year high stood at -$13.5 million during FY2020, with a 5-year trough of -$146.9 million in FY2023.
  • In the last 3 years, Day One Biopharmaceuticals' Cash from Operations had a median value of -$109.9 million in 2022 and averaged -$111.6 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Cash from Operations plummeted by 259.84% in 2021 and then soared by 46.81% in 2024.
  • Yearly analysis of 5 years shows Day One Biopharmaceuticals' Cash from Operations stood at -$13.5 million in 2020, then crashed by 259.84% to -$48.5 million in 2021, then slumped by 126.36% to -$109.9 million in 2022, then slumped by 33.66% to -$146.9 million in 2023, then surged by 46.81% to -$78.1 million in 2024.